PMID- 38066907
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240215
IS  - 1520-4383 (Electronic)
IS  - 1520-4391 (Print)
IS  - 1520-4383 (Linking)
VI  - 2023
IP  - 1
DP  - 2023 Dec 8
TI  - Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed 
      lymphomas.
PG  - 370-381
LID - 10.1182/hematology.2023000438 [doi]
AB  - Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin 
      lymphomas have historically poor survival outcomes, with chimeric antigen 
      receptor T-cell (CAR-T) therapy now presenting a curative option for a subset of 
      those patients. However, with the approval of several novel bispecific monoclonal 
      antibody (BsAb) therapies with considerable activity in R/R aggressive large 
      B-cell lymphomas (LBCL), patients and oncologists will be faced with decisions 
      regarding how to sequence CAR-T and BsAb therapies based on patient- and 
      disease-related factors. In this review, we compare CAR-T and BsAb therapies for 
      R/R LBCL, highlighting data on the efficacy and toxicity of each treatment 
      paradigm, and provide a roadmap for sequencing these highly effective therapies.
CI  - Copyright (c) 2023 by The American Society of Hematology.
FAU - Major, Ajay
AU  - Major A
AD  - Division of Hematology, Department of Medicine, University of Colorado School of 
      Medicine, Aurora, CO.
FAU - Kamdar, Manali
AU  - Kamdar M
AD  - Division of Hematology, Department of Medicine, University of Colorado School of 
      Medicine, Aurora, CO.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antibodies, Bispecific)
SB  - IM
MH  - Humans
MH  - *Receptors, Chimeric Antigen/therapeutic use
MH  - Immunotherapy, Adoptive
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - *Antibodies, Bispecific/therapeutic use
MH  - Cell- and Tissue-Based Therapy
PMC - PMC10727048
COIS- Ajay Major: no competing financial interests to declare. Manali Kamdar declares 
      research support from Novartis; consultancy from AbbVie, AstraZeneca, 
      Celgene/Bristol-Myers Squibb, Adaptive Biotechnologies, ADC Therapeutics, 
      Beigene, Genentech, Impact Bio, Syncopation, and Caribou Biosciences; speaker's 
      bureau from SeaGen; and data monitoring committee from Celgene and Genentech.
EDAT- 2023/12/09 10:45
MHDA- 2023/12/17 09:43
PMCR- 2024/12/08
CRDT- 2023/12/09 01:01
PHST- 2024/12/08 00:00 [pmc-release]
PHST- 2023/12/17 09:43 [medline]
PHST- 2023/12/09 10:45 [pubmed]
PHST- 2023/12/09 01:01 [entrez]
AID - 506455 [pii]
AID - 2023000438 [pii]
AID - 10.1182/hematology.2023000438 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):370-381. doi: 
      10.1182/hematology.2023000438.